FDA Releases Updated Good Clinical Practice Guidance for Trials
Published Date: 9/9/2025
Notice
Summary
The FDA just released the final version of the E6(R3) Good Clinical Practice guidance, which helps drug makers run safer, smarter clinical trials using modern tech and risk-based methods. This update affects anyone involved in clinical trials by encouraging simpler, quality-focused approaches that save time and resources. Get ready to follow these new rules soon to keep trials efficient and reliable!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Modernized Good Clinical Practice Rules
The FDA released the final E6(R3) Good Clinical Practice guidance, which outlines flexible, modern rules for running clinical trials. It emphasizes quality-by-design, proportionality, and risk-based approaches, encourages use of innovative technology, and finalizes the draft issued June 7, 2023; annex 2 will be added later.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-17308, New England Fishery Management Council; Public Meeting
The New England Fishery Management Council is hosting a 3-day meeting where people can join in person or online to talk about rules for fishing in New England waters. This affects fishermen, seafood businesses, and anyone who loves fresh fish from the area. They’ll discuss important changes soon, so keep an eye out for new fishing rules that could impact when and how much fish can be caught.
Next: 2025-17312, Record of Decision for the Enhanced Integrated Air and Missile Defense System on Guam Environmental Impact Statement
The U.S. is moving forward with building and running a new, super-smart missile defense system on Guam to protect against fast-changing threats. This plan affects the military, local communities, and the environment, with careful steps to reduce any harm. Construction and operations will start soon, backed by strong government support and funding to keep Guam safe.